Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2016
At a glance
- Drugs Imatinib (Primary) ; Dasatinib; Nilotinib; Radotinib
- Indications Chronic myeloid leukaemia; Leukaemia; Myeloproliferative disorders
- Focus Therapeutic Use
- Acronyms IDEAL-E
- 12 Jul 2016 Planned End Date changed from 1 Oct 2023 to 1 May 2023.
- 12 Jul 2016 Planned primary completion date changed from 1 Oct 2023 to 1 May 2023.
- 12 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.